Analyst Reco. OncoCyte Corporation

Equities

OCX

US68235C2061

Market Closed - Nasdaq Other stock markets 21:30:00 02/05/2024 BST			5-day change	1st Jan Change
2.779 ^USD	+9.00%		+13.91%	+11.18%

04-25	OncoCyte Corporation announced that it has received $15.807655 million in funding	CI
04-16	Broadwood Capital, Inc. Engages with OncoCyte Corporation	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Needham Adjusts Price Target on OncoCyte to $3.60 From $4.25, Maintains Buy Rating	11-09	MT
Benchmark Adjusts Price Target on OncoCyte to $5 From $9, Maintains Speculative Buy Rating	24/08/23	MT
Piper Sandler Adjusts Price Target on OncoCyte to $3.50 From $6, Keeps Neutral Rating	15/08/23	MT
Needham Adjusts OncoCyte's Price Target to $4.25 From $9, Keeps Buy Rating	10/08/23	MT
Needham Trims Price Target on OncoCyte to $0.45 From $1.40, Keeps Buy Rating	04/04/23	MT
Lake Street Downgrades Oncocyte to Hold From Buy, Cuts Price Target to $0.50 From $3	01/12/22	MT
Piper Sandler Downgrades OncoCyte to Neutral From Overweight, Adjusts Price Target to $0.50 From $1	18/11/22	MT
Piper Sandler Trims Price Target on OncoCyte to $1 From $1.50, Maintains Overweight Rating	14/11/22	MT
Lake Street Adjusts OncoCyte Price Target to $3 From $6, Maintains Buy Rating	11/08/22	MT
Needham Trims OncoCyte's Price Target to $2.10 From $2.25 on 'Lower Revenue Estimates;' Buy Rating Kept	11/08/22	MT
Stephens Downgrades OncoCyte to Equalweight From Overweight, Adjusts Price Target to $1.25 From $2	24/05/22	MT
Piper Sandler Trims OncoCyte's Price Target to $1.40 From $1.80, Maintains Overweight Rating	16/05/22	MT
Needham Adjusts OncoCyte's Price Target to $2.25 From $4 on 'Peer Multiple Compression,' Reiterates Buy Rating	12/05/22	MT
Piper Sandler Adjusts OncoCyte's Price Target to $1.80 from $3.10, Keeps Overweight Rating	18/03/22	MT
KeyBanc Downgrades OncoCyte to Sector Weight From Overweight, Citing Need for Added Capital, Removes $7 Price Target	14/03/22	MT
Lake Street Adjusts OncoCyte Price Target to $6 From $11, Maintains Buy Rating	11/03/22	MT
Needham Adjusts OncoCyte's Price Target to $4 From $5, Citing Peer Multiple Compression; Buy Rating Kept	11/03/22	MT
Stephens Initiates OncoCyte With Overweight Rating, $3.10 Price Target	07/01/22	MT
Stephens Starts OncoCyte at Overweight With $3.10 Price Target	07/01/22	MT
Needham Lowers OncoCyte's Price Target to $5 From $7, Maintains Buy Rating	15/12/21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. OncoCyte Corporation

Equities

OCX

US68235C2061

Analyst Reco.

Filters